bluebird bio, Inc. (BLUE)

bluebird bio Statistics

Total Valuation

bluebird bio has a market cap or net worth of $96.78 million. The enterprise value is $350.99 million.

Market Cap	96.78M
Enterprise Value	350.99M

Important Dates

The next estimated earnings date is Tuesday, November 5, 2024, before market open.

Earnings Date	Nov 5, 2024
Ex-Dividend Date	n/a

Share Statistics

bluebird bio has 193.91 million shares outstanding. The number of shares has increased by 62.35% in one year.

Shares Outstanding	193.91M
Shares Change (YoY)	+62.35%
Shares Change (QoQ)	+0.29%
Owned by Insiders (%)	0.46%
Owned by Institutions (%)	40.82%
Float	193.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.43
Forward PS	0.52
PB Ratio	1.88
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	6.39
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.68, with a Debt / Equity ratio of 7.47.

Current Ratio	0.68
Quick Ratio	0.53
Debt / Equity	7.47
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-18.80

Financial Efficiency

Return on equity (ROE) is -186.70% and return on invested capital (ROIC) is -41.93%.

Return on Equity (ROE)	-186.70%
Return on Assets (ROA)	-36.24%
Return on Capital (ROIC)	-41.93%
Revenue Per Employee	$146,400
Profits Per Employee	-$851,336
Employee Count	375
Asset Turnover	0.09
Inventory Turnover	3.24

Taxes

Income Tax	-25,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.69% in the last 52 weeks. The beta is 0.79, so bluebird bio's price volatility has been lower than the market average.

Beta (5Y)	0.79
52-Week Price Change	-82.69%
50-Day Moving Average	0.55
200-Day Moving Average	0.97
Relative Strength Index (RSI)	44.53
Average Volume (20 Days)	5,312,222

Short Selling Information

The latest short interest is 48.99 million, so 25.26% of the outstanding shares have been sold short.

Short Interest	48.99M
Short Previous Month	48.40M
Short % of Shares Out	25.26%
Short % of Float	25.38%
Short Ratio (days to cover)	6.46

Income Statement

In the last 12 months, bluebird bio had revenue of $54.90 million and -$319.25 million in losses. Loss per share was -$2.08.

Revenue	54.90M
Gross Profit	-21.23M
Operating Income	-350.38M
Pretax Income	-91.14M
Net Income	-319.25M
EBITDA	-302.11M
EBIT	-350.38M
Loss Per Share	-$2.08

Balance Sheet

The company has $144.07 million in cash and $395.64 million in debt, giving a net cash position of -$251.57 million or -$1.30 per share.

Cash & Cash Equivalents	144.07M
Total Debt	395.64M
Net Cash	-251.57M
Net Cash Per Share	-$1.30
Equity (Book Value)	52.98M
Book Value Per Share	0.27
Working Capital	-94.41M

Cash Flow

In the last 12 months, operating cash flow was -$245.12 million and capital expenditures -$5.09 million, giving a free cash flow of -$250.20 million.

Operating Cash Flow	-245.12M
Capital Expenditures	-5.09M
Free Cash Flow	-250.20M
FCF Per Share	-$1.29

Margins

Gross Margin	-38.67%
Operating Margin	-638.21%
Pretax Margin	-581.56%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-394.16%

Dividends & Yields

bluebird bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-62.35%
Shareholder Yield	-62.35%
Earnings Yield	-321.12%
FCF Yield	-251.66%

Analyst Forecast

The average price target for bluebird bio is $4.63, which is 827.67% higher than the current price. The consensus rating is "Hold".

Price Target	$4.63
Price Target Difference	827.67%
Analyst Consensus	Hold
Analyst Count	11
Revenue Growth Forecast (5Y)	74.92%
EPS Growth Forecast (5Y)	-54.55%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

bluebird bio has an Altman Z-Score of -13.2 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-13.2
Piotroski F-Score	2